|
Potential Topic for an event concerning obtaining the right level of Nitrosamine Risk Assessment information from your CMOs
|
|
22
|
1665
|
September 5, 2024
|
|
📅 FDA - CRCG Updates on Approaches to Acceptable Intakes of Nitrosamine Drug Substance Related Impurities (NDSRIs) and Bioequivalence Assessment for Reformulated Drug Products -Event
|
|
1
|
997
|
August 14, 2024
|
|
IPEC Webinar on the role of excipients in determine N-nitrosamine risks
|
|
3
|
479
|
July 24, 2024
|
|
Classification of potentially mutagenic impurities under the ICH M7 guideline -Event
|
|
0
|
403
|
July 23, 2024
|
|
Nitrosamine in vivo mutagenicity workshop
|
|
10
|
814
|
July 22, 2024
|
|
Nitrosamine impurities in medicines (presented at the ARCS Annual Conference 2024)
|
|
12
|
1159
|
July 17, 2024
|
|
USP India - Nitrosamines panel discussion at USP Science Conclave
|
|
0
|
373
|
July 10, 2024
|
|
EPR Podcast Ep 26 – Navigating Nitrosamine Impurities
|
|
0
|
383
|
June 26, 2024
|
|
Predicting Nitrosamine Formation in the Solid State
|
|
3
|
781
|
June 24, 2024
|
|
Common Template for initial assessment of Nitrosamine impurities
|
|
0
|
684
|
June 20, 2024
|
|
Insights from the Lhasa Limited and IPEC Europe Nitrites collaborative meeting
|
|
1
|
531
|
June 16, 2024
|
|
🇺🇸 FDA - Fiscal Year 2024 Generic Drug Science and Research Initatives Public Workshop
|
|
20
|
1958
|
September 5, 2024
|
|
🇲🇽 Conferencia USP Nitrosaminas en México presencial 21-Marzo
|
|
4
|
781
|
May 27, 2024
|
|
Managing the complexities of NDSRI method development: The N-nitroso propranolol case story
|
|
0
|
549
|
May 14, 2024
|
|
Using the Carcinogenicity Potency Categorization Algorithm to Predict N-Nitrosamine Carcinogenicity -Webinar
|
|
0
|
375
|
May 13, 2024
|
|
🇺🇸 FDA CDER Generic Drug Forum (GDF) 2024
|
|
5
|
1401
|
April 14, 2024
|
|
📅 Ascorbic Acid And Alpha-Tocopherol As Nitrite Scavengers - An Elegant And Simple Solution To Mitigate Nitrosamines In Drug Products -Event
|
|
0
|
891
|
April 5, 2024
|
|
USP User Forum in 🇨🇦 Toronto
|
|
0
|
241
|
March 12, 2024
|
|
Read-across Masterclass: How To Facilitate Your Acceptable Intake Limit Setting For Nitrosamines
|
|
0
|
380
|
March 7, 2024
|
|
HESI Open call to Q(SAR) and QM working group
|
|
3
|
782
|
February 20, 2024
|
|
TALK SERIES: Navigating Nitrosamine and NDSRIs regulations with Dr. Reddy´s Laboratories
|
|
1
|
776
|
February 11, 2024
|
|
Exploring the CPCA Framework: Defining Acceptable Intake for NDSRIs -Event
|
|
2
|
900
|
January 10, 2024
|
|
Upcoming and recorded Lhasa webinars
|
|
3
|
911
|
December 21, 2023
|
|
Nitrosamine Impurities Deadline: Are Your Products Compliant?
|
|
6
|
703
|
December 6, 2023
|
|
8th Impurities: Genotoxic, Nitrosamine, & Beyond Summit
|
|
1
|
1071
|
December 1, 2023
|
|
10º encontro Farmacopeia Brasileira
|
|
0
|
523
|
November 30, 2023
|
|
Free Webinar: Nitrosamines in Drug Products
|
|
12
|
1887
|
November 16, 2023
|
|
Nitrosamine Risk Reduction In Pharmaceutical Formulations Webinar
|
|
1
|
884
|
November 6, 2023
|
|
USP, EDQM, JP, IPC through Pharmacopeial Discussion Group on Nitrosamines
|
|
2
|
503
|
November 2, 2023
|
|
FDA - Pharmaceutical Quality Symposium
|
|
1
|
830
|
November 1, 2023
|